Top Markets
Coin of the day
Acticor Biotech SAS Acticor Biotech SAS

Acticor Biotech SAS

ALACT
株式のランク #37014
Acticor Biotech SAS is a clinical-stage biotechnology firm focused on creating... Acticor Biotech SAS is a clinical-stage biotechnology firm focused on creating therapies for the acute phase of thrombotic conditions. The company's lead compound, glenzocimab, is a humanized monoclonal antibody fragment specifically designed to target a particular platelet glycoprotein. Currently, Acticor Biotech is advancing two clinical programs, both in Phase II/III, for the registration of treatments for ischemic stroke. Additionally, it is conducting two other Phase II trials concerning significant cardiovascular emergencies, with anticipated clinical data expected from both its ischemic stroke research and studies related to COVID-19 respiratory distress syndrome. Established in 2013, the company operates from its headquarters in Paris, France.
株価
$0.25974701
最終同期: 2025-01-06
時価総額
$2.04M
変化(1日)
0.74%
変化(1年)
0.00%
FR
取引 Acticor Biotech SAS (ALACT)

カテゴリー

Acticor Biotech SAS(ALACT)のEPS
June 2024 時点のEPS TTM: $-1.95
Acticor Biotech SASの最新の財務報告と株価によると、同社の現在のEPS(TTM)は$-1.95です。2022年末には、EPSは$-1.62で、2021年のEPS$-1.84と減少でした。
Acticor Biotech SASのEPS履歴(2010から2026まで)
各年末時点のEPS
EPS 変化
2026 (TTM) $-1.95 -99.90%
2023 0.00 -99.90%
2022 $-1.62 -12.08%
2021 $-1.84 26.05%
2020 $-1.46 35.69%
2019 $-1.08 -51.93%
2018 $-2.24 -40.33%
2017 $-3.76 2,449.69%
2016 $-0.15 -66.91%
2015 $-0.45 26.87%
2014 $-0.35 -143.25%
2013 $0.81 -9.55%
2012 $0.90 35.87%
2011 $0.66 462.35%
2010 $0.12 0.00%
同様の企業または競合他社のEPS
企業 EPS EPSの差
$17.32 -986.39%
US
$27.74 -1,519.65%
NL
$-5.29 170.73%
AU
$-7.98 308.39%
US
- -
CH